Subscribe today! Our May newsletter is filled with lots of initiatives to create awareness for bladder cancer including blogs, podcasts, helpful facts, webinars and more. Bladder cancer is the 5th most common cancer in Canada and there are currently 80,000+ Canadians living with a bladder cancer diagnosis. This year, 12,500 more Canadians will be diagnosed. OurRead more
Blog
By: Tom Eremondi Read time: 3.5 minutes Admittedly old school, Gerry Ross’ approach to dealing with a local walk sponsor nurtured and enhanced the relationship to a surprising level. This story, however, dates back about five years ago when the Kingston resident was diagnosed with both bladder and prostate cancer. As he was undergoing treatment,Read more
Uncertain times are upon us, around the world, as we globally respond to the coronavirus (COVID-19) that is affecting us all on some level. Many members of our bladder cancer community are directing questions our way about how the this virus might affect their health and treatments. We will be answering many of these questions after consulting with theRead more
(The following content is sourced from various sites advising on the coronavirus. For more information, please see the end of this article for additional resources. Photo Credit: CDC) As news of the coronavirus (COVID-19) continues to spread globally, many people have become concerned about contracting this disease. For cancer patients and survivors that have a compromisedRead more
In a recent press release, Janssen Pharmaceutical Companies of Johnson & Johnson have announced that they have received approval from Health Canada for BALVERSA™ (erdafitinib), the first FGFR Kinase inhibitor for the treatment of patients with locally advanced or metastatic urothelial carcinoma with certain FGFR genetic alterations. Health Canada has approved the therapy on the conditionRead more
Bladder Cancer Canada was recently reviewed by Charity Intelligence, an independent organization that researches Canadian charities so that donors can be well informed and give intelligently. Of the 750 charities that Charity Intelligence has reviewed, only 15% received the highest ranking, four stars. Sixty Canadian cancer-related charities were reviewed, and Bladder Cancer Canada was among onlyRead more
IMPORTANT UPDATE – March 9, 2020 Bladder Cancer Canada (BCC) and its Medical Advisory Board were advised by Merck Canada in November 2019 that they would continue to face challenges in the supply of the TICE strain of Bacillus Calmette-Guerin (BCG) in Canada for 2020. As the only supplier of BCG in Canada, Merck established an allocation planRead more
This year we are pleased to announce two recipients for the Bladder Cancer Canada Research Grant – Dr. W. Kassouf (McGill University) and Co-Investigators, Drs’. Kulkarni (University of Toronto) and Breau (The University of Ottawa). Each project will receive a $50,000 grant. Dr. W. Kassouf – Does combination of radiation plus PD-L1 blockade induceRead more
As BCC celebrates its 10th anniversary in 2019, there is another reason for celebration: Dr. Wes Kassouf has been awarded the inaugural BCC Medical Leadership Award for his remarkable service and dedication to BCC and the patients it supports. Dr. Kassouf has been Chair of the Medical Advisory and Medical Research Boards of BCC sinceRead more
2018 Impact Report – Read how your support has made a difference When Jack Moon and David Guttman, as bladder cancer survivors, founded Bladder Cancer Canada in 2009, we might have hoped but had no idea that it would become what it is today. That’s why, during this 10th anniversary year, we’re pleased to share BCC’sRead more
